On March 24 Russell acquired 500,000 shares in the company and also holds 25 million options.
She has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.
Her experience has been gained at a number of leading companies including, Amgen (NASDAQ:AMGN), Eli Lilly (NASDAQ:LLY), US Bioscience/Medimmune Oncology, Cephalon Inc (NASDAQ:CEPH), Teva Pharmaceuticals (NASDAQ:TEVA), TetraLogic and Innocoll Holdings Plc.
This on-market purchase followed another last week by managing director and chief executive officer Leslie Chong who purchased 475,240 shares and now holds 4,387,124 shares and 77,098,765 options.
Focus of operations
In February, the company outlined its focus of operations in the short to medium term in its latest half-year report, stating that it would be directed towards the development of CF33 Read More – Source